403509-10-4

Basic information

• Product Name: N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dichloropropyl]-3-fluorobenzamide
• Synonyms: N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dichloropropyl]-3-fluorobenzamide
• CAS NO: 403509-10-4
• Molecular Weight: 367.21
• Mol File: 403509-10-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dichloropropyl]-3-fluorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dichloropropyl]-3-fluorobenzamide(403509-10-4)
• EPA Substance Registry System: N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dichloropropyl]-3-fluorobenzamide(403509-10-4)

Safety Data

• Hazardous Substances Data: 403509-10-4(Hazardous Substances Data)

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 27313-32-2 2,2-dichloropropanal 
• 455-37-8 3-fluorobenzamide 

Relevant articles and documents

Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder

A series of novel cyanoguanidine derivatives was designed and synthesized. Condensation of N-(1-benzotriazol-1-yl-2,2-dichloropropyl)-substituted benzamides with N-(substituted-pyridin-3-yl)-N′-cyanoguanidines furnished N-{2,2-dichloro-1-[N′-(substituted-pyridin-3-yl)-N′-cyanoguanidino] propyl}-substituted benzamide derivatives. These agents were glyburide-reversible potassium channel openers and hyperpolarized human bladder cells as assessed by the FLIPR membrane potential dye (KATP-FMP). These compounds were also potent full agonists in relaxing electrically stimulated pig bladder strips, an in vitro model of overactive bladder. The most active compound 9 was evaluated for in vivo efficacy and selectivity in a pig model of bladder instability. Preliminary pharmacokinetic studies in dog demonstrated excellent oral bioavailability and a t1/2 of 15 h. The synthesis, SAR studies, and biological properties of these agents are discussed.

Potassium channel openers

Compounds of formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.